Related Experiment Video
Updated: May 16, 2026
07:39
The Establishment of a Lung Colonization Assay for Circulating Tumor Cell Visualization in Lung Tissues
Published on: June 16, 2018
Circulating tumor cells in lung cancer
Rachel Young1, Emma Pailler, Fanny Billiot
1Institut de Cancérologie Gustave Roussy, Villejuif, France.
Acta Cytologica
|December 5, 2012
Summary
Circulating tumor cells (CTCs) are promising cancer biomarkers. Detecting CTCs, especially in lung cancer, remains challenging but offers potential for personalized medicine and
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background:
- Circulating tumor cells (CTCs) show promise as biomarkers for prognosis in various cancers.
- Current CTC detection methods lack universality and face challenges, particularly in lung cancer due to nonepithelial characteristics and marker loss during metastasis.
- The rise of personalized medicine fuels advancements in molecular characterization of CTCs.
Purpose of the Study:
- To review the current state of CTC detection technologies.
- To highlight challenges and advancements in CTC detection for lung cancer.
- To explore the future potential of CTCs as a 'liquid biopsy' for patient management.
Main Methods:
- Review of existing literature on CTC detection techniques.
- Discussion of molecular characterization methods like FISH and RT-PCR for CTCs.
- Analysis of CTC detection challenges in specific cancers, notably lung cancer.
Main Results:
- CTC enumeration correlates with patient prognosis in several cancers.
- Lung cancer CTC detection is difficult due to cellular heterogeneity and marker expression.
- Molecular profiling of CTCs (e.g., EGFR, HER2, KRAS) enables real-time characterization.
Conclusions:
- CTCs represent a significant advancement in cancer diagnostics and prognostics.
- Overcoming detection challenges in lung cancer is crucial for clinical application.
- CTCs hold great potential as a non-invasive 'liquid biopsy' for guiding treatment strategies.
